The pathogenesis of Alzheimer’s disease (AD) involves various immune-related phenomena; however, the mechanisms underlying these immune phenomena and the potential hub genes involved therein are unclear. An understanding of AD-related immune hub genes and regulatory mechanisms would help develop new immunotherapeutic targets.
Objective:
The aim of this study was to explore the hub genes and the mechanisms underlying the regulation of competitive endogenous RNA (ceRNA) in immune-related phenomena in AD pathogenesis.
Methods:
We used the GSE48350 data set from the Gene Expression Omnibus database and identified AD immune-related differentially expressed RNAs (DERNAs). We constructed protein–protein interaction (PPI) networks for differentially expressed mRNAs and determined the degree for screening hub genes. By determining Pearson’s correlation coefficient and using StarBase, DIANA-LncBase, and Human MicroRNA Disease Database (HMDD), the AD immune-related ceRNA network was generated. Furthermore, we assessed the upregulated and downregulated ceRNA subnetworks to identify key lncRNAs.
Results:
In total, 552 AD immune-related DERNAs were obtained. Twenty hub genes, including PIK3R1, B2M, HLA-DPB1, HLA-DQB1, PIK3CA, APP, CDC42, PPBP, C3AR1, HRAS, PTAFR, RAB37, FYN, PSMD1, ACTR10, HLA-E, ARRB2, GGH, ALDOA, and VAMP2 were identified on PPI network analysis. Furthermore, upon microRNAs (miRNAs) inhibition, we identified LINC00836 and DCTN1-AS1 as key lncRNAs regulating the aforementioned hub genes.
Conclusion:
AD-related immune hub genes include B2M, FYN, PIK3R1, and PIK3CA, and lncRNAs LINC00836 and DCTN1-AS1 potentially contribute to AD immune-related phenomena by regulating AD-related hub genes.
GourasGK, TsaiJ, NaslundJ, VincentB, EdgarM, CheclerF, GreenfieldJP, HaroutunianV, BuxbaumJD, XuH, GreengardP, RelkinNR (2000) Intraneuronal Abeta42 accumulation in human brain. Am J Pathol156, 15–20.
2.
ArriagadaPV, GrowdonJH, Hedley-WhyteET, HymanBT (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology42, 631–639.
3.
ScheffSW, NeltnerJH, NelsonPT (2014) Is synaptic loss a unique hallmark of Alzheimer’s disease. Biochem Pharmacol88, 517–528.
4.
SelkoeDJ (2002) Alzheimer’s disease is a synaptic failure. Science298, 789–791.
5.
GuerreiroR, WojtasA, BrasJ, CarrasquilloM, RogaevaE, MajounieE, CruchagaC, SassiC, KauweJS, YounkinS; Alzheimer Genetic Analysis Group (2013) TREM2 variants in Alzheimer’s disease. N Engl J Med368, 117–127.
6.
JonssonT, StefanssonH, SteinbergS, JonsdottirI, JonssonPV, SnaedalJ, BjornssonS, HuttenlocherJ, LeveyAI, LahJJ (2013) Variant of TREM2 associated with the risk of Alzheimer’s disease. N Engl J Med368, 107–116.
7.
HollingworthP, HaroldD, SimsR, GerrishA, LambertJC, CarrasquilloMM, AbrahamR, HamshereML, PahwaJS, MoskvinaV; Alzheimer’s Disease Neuroimaging Initiative; CHARGE consortium; EADI1 consortium (2011) Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat Genet43, 429–435.
8.
LambertJC, HeathS, EvenG, CampionD, SleegersK, HiltunenM, CombarrosO, ZelenikaD, BullidoMJ, TavernierB; European Alzheimer’s Disease Initiative Investigators (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nat Genet41, 1094–1099.
9.
LambertJC, Ibrahim-VerbaasCA, HaroldD, NajAC, SimsR, BellenguezC, DeStafanoAL, BisJC, BeechamGW, Grenier-BoleyB; European Alzheimer’s Disease Initiative (EADI); Genetic and Environmental Risk in Alzheimer’s Disease; Alzheimer’s Disease Genetic Consortium; Cohorts for Heart and Aging Research in Genomic Epidemiology (2013) Metaanalysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet45, 1452–1458.
10.
JansenIE, SavageJE, WatanabeK, BryoisJ, WilliamsDM, SteinbergS, SealockJ, KarlssonIK, HäggS, AthanasiuL (2019) Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk. Nature51, 404–413.
11.
UlrichJD, FinnMB, WangY, ShenA, MahanTE, JiangH, StewartFR, PiccioL, ColonnaM, HoltzmanDM (2014) Altered microglial response to Aβ plaques in APPPS1-21 mice heterozygous for TREM2. Mol Neurodegener9, 1–9.
12.
TalwarP, KushwahaS, GuptaR, AgarwalR (2019) Systemic immune dyshomeostasis model and pathways in Alzheimer’s disease. Front Aging Neurosci11, 290.
13.
BatistaCRA, GomesGF, Candelario-JalilE, FiebichBL, De OliveiraACP (2019) Lipopolysaccharide-Induced neuroinflammation as a bridge to understand neurodegeneration. Int J Mol Sci20, 2293.
14.
BruggB, DubreuilYL, HuberG, WollmanEE, Delhaye-BouchaudN, MarianiJ (1995) Inflammatory processes induce beta-amyloid precursor protein changes in mouse brain. Proc Natl Acad Sci U S A92, 3032–3035.
AlexandrovPN, ZhaoY, JonesBM, BhattacharjeeS, LukiwWJ (2013) Expression of the phagocytosis-essential protein TREM2 is down-regulated by an aluminum-induced miRNA-34a in a murine microglial cell line. J Inorg Biochem128, 267–269.
19.
ZhaoY, BhattacharjeeS, JonesBM, DuaP, AlexandrovPN, HillJM, LukiwWJ (2013) Regulation of TREM2 expression by an NF-κB-sensitive miRNA-34a. Neuroreport24, 318–323.
20.
GardnerOK, WangL, Van BoovenD, WhiteheadPL, Hamilton-NelsonKL, AdamsLD, StarksTD, HofmannNK, VanceJM, CuccaroML, MartinER, ByrdGS, HainesJL, BushWS, BeechamGW, Pericak-VanceMA, GriswoldAJ (2019) RNA editing alterations in a multi-ethnic Alzheimer disease cohort converge on immune and endocytic molecular pathways. Hum Mol Genet28, 3053–3061.
21.
ZhangY, LiuD, WangL, WangS, YuX, DaiE, LiuX, LuoS, JiangW (2015) Integrated systems approach identifies risk regulatory pathways and key regulators in coronary artery disease. J Mol Med93, 1381–1390.
22.
MercerTR, DingerME, MattickJS (2009) Long non-coding RNAs: Insights into functions. Nat Rev Genet10, 155–159.
23.
SalmenaL, PolisenoL, TayY, KatsL, PandolfiPP (2011) A ceRNA hypothesis: The Rosetta Stone of a hidden RNA language. Cell146, 353–358.
24.
BarrettT, TroupDB, WilhiteSE, LedouxP, RudnevD, EvangelistaC, KimIF, SobolevaA, TomashevskyM, EdgarR (2007) NCBI GEO: Mining tens of millions of expression profiles–database and tools update. Nucleic Acids Res35, 760–765.
25.
BraschiB, DennyP, GrayK, JonesT, SealR, TweedieS, YatesB, BrufordE (2019) Genenames.org: The HGNC and VGNC resources in 2019. Nucleic Acids Res47, 786–792.
26.
Gene Ontology Consortium (2010) The gene ontology in 2010: Extensions and refinements. Nucleic Acids Res38, 331–335.
27.
KanehisaM, GotoS (2000) KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res28, 27–30.
28.
SzklarczykD, MorrisJH, CookH, KuhnM, WyderS, SimonovicM, SantosA, DonchevaNT, RothA, BorkP, JensenLJ, von MeringC (2017) The STRING database in 2017: Quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res45, 362–368.
29.
ShannonP, MarkielA, OzierO, BaligaNS, WangJT, RamageD, AminN, SchwikowskiB, IdekerT (2003) Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res13, 2498–2504.
30.
ZhouY, ZhouB, PacheL, ChangM, KhodabakhshiAH, TanaseichukO, BennerC, ChandaSK (2019) Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun10, 1–10.
31.
HuangZ, ShiJ, GaoY, CuiC, ZhangS, LiJ, ZhouY, CuiQ (2019) HMDD v3.0: A database for experimentally supported human microRNA-disease associations. Nucleic Acids Res47, 1013–1017.
CunninghamBA, BerggardI (1974) Structure, evolution and significance of beta2-microglobulin. Transplant Rev21, 3–14.
35.
MátraiZ, NémethJ, MiklósK, SzabóZ, MassziT (2009) Serum beta2-microglobulin measured by immunonephelometry: Expression patterns and reference intervals in healthy adults. Clin Chem Lab Med47, 585–589.
36.
BrewBJ, DunbarN, PembertonL, KaldorJ (1996) Predictive markers of AIDS dementia complex: CD4 cell count and cerebrospinal fluid concentrations of β2-microglobulin and neopterin. J Infect Dis174, 294–298.
37.
McArthurJC, Nance-SprosonTE, GriffinDE, HooverD, SelnesOA, MillerEN, MargolickJB, CohenBA, FarzadeganH, SaahA (1992) The diagnostic utility of elevation in cerebrospinal fluid beta 2-microglobulin in HIV-1 dementia. Multicenter AIDS Cohort Study. Neurology42, 1707–1712.
38.
DominiciR, FinazziD, PolitoL, OldoniE, BugariG, MontanelliA, GuaitaA (2018) Comparison of β2-microglobulin serum level between Alzheimer’s patients, cognitive healthy and mild cognitive impaired individuals. Biomarkers23, 603–608.
39.
VanniS, ModaF, ZattoniM, BistaffaE, CeccoED, RossiM, GiacconeG, TagliaviniF, HaïkS, DeslysJP, ZanussoG, IronsideJW, FerrerI, KovacsGG, LegnameG (2017) Differential overexpression of SERPINA3 in human prion diseases. Sci Rep7, 1–13.
40.
LaurénJ, GimbelD, NygaardH, GilbertJ, StrittmatterS (2009) Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature457, 1128–1132.
41.
NygaardHB, StrittmatterSM (2009) Cellular prion protein mediates the toxicity of beta-amyloid oligomers: Implications for Alzheimer disease. Arch Neurol66, 1325–1328.
42.
UmJW, NygaardHB, HeissJK, KostylevMA, StagiM, VortmeyerA, WisniewskiT, GuntherEC, StrittmatterSM (2012) Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci15, 1227.
43.
BlissTV, LomoT (1973) Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path. J Physiol232, 331–356.
44.
MalenkaRC, NicollRA (1999) Long-term potentiation-a decade of progress. Science285, 1870–1874.
45.
JimenezB, VolpertOV, CrawfordSE, FebbraioM, SilversteinRL, BouckN (2000) Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med6, 41–48.
Wyss-CorayT, McConlogueL, KindyM, SchmidtAM, DuSY, SternDM (2001) Key signaling pathways regulate the biological activities and accumulation of amyloid-beta. Neurobiol Aging22, 967–973.
48.
NygaardHB, WagnerAF, BowenGS, GoodSP, MacAvoyMG, StrittmatterKA, KaufmanAC, RosenbergBJ, Sekine-KonnoT, VarmaP, ChenK, KoleskeAJ, ReimanEM, StrittmatterSM, van DyckCH (2015) A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer’s diseas. Alzheimers Res Ther7, 35.
49.
ZhangD, HuX, QianL, ChenSH, ZhouH, WilsonB, MillerDS, HongJS (2011) . Microglial MAC1 receptor and PI3K are essential in mediating β-amyloid peptide-induced microglial activation and subsequent neurotoxicity. J Neuroinflamm8, 3.
50.
LiolitsaD, PowellJ, LovestoneS (2002) Genetic variability in the insulin signalling pathway may contribute to the risk of late onset Alzheimer’s disease. J Neurol Neurosurg Psychiatry73, 261–266.
51.
Mendoza-NaranjoA, Gonzalez-BillaultC, MaccioniRB (2007) Abeta1-42 stimulates actin polymerization in hippocampal neurons through Rac1 and Cdc42 Rho GTPases. J Cell Sci120, 279–288.
52.
MatusA (2000) Actin-based plasticity in dendritic spines. Science290, 754–758.
53.
PenzesP, VanleeuwenJ-EE (2011) Impaired regulation of synaptic actin cytoskeleton in Alzheimer’s disease. Brain Res Rev67, 184–192.
54.
LeeY, HanS, KimD, KimD, HorgousluogluE, RisacherSL, SaykinAJ, NhoK (2018) Genetic variation affecting exon skipping contributes to brain structural atrophy in Alzheimer’s disease. AMIA Jt Summits Transl Sci Proc2017, 124–131.
55.
LitvinchukA, WanYW, SwartzlanderDB, ChenF, ColeA, PropsonNE, WangQ, ZhangB, LiuZ, ZhengH (2018) Complement C3aR inactivation attenuates tau pathology and reverses an immune network deregulated in tauopathy models and Alzheimer’s disease. Neuron100, 1337–1353.
56.
ShenL, LiaoL, ChenC, GuoY, SongD, WangY, ChenY, ZhangK, YingM, LiS, LiuQ, NiJ (2017) Proteomics analysis of blood serums from Alzheimer’s disease patients using iTRAQ labeling technology. J Alzheimers Dis56, 361–378.
57.
JiangT, YuJT, WangYL, WangHF, ZhangW, HuN, TanL, SunL, TanMS, ZhuXC, TanL (2014) The genetic variation of ARRB2 is associated with late-onset Alzheimer’s disease in Han Chinese. Curr Alzheimer Res1, 408–412.
58.
RussellCL, SemerdjievaS, EmpsonRM, AustenBM, BeesleyPW, AlifragisP (2012) Amyloid-β acts as a regulator of neurotransmitter release disrupting the interaction between synaptophysin and VAMP2. PLoS One7, e43201.
59.
XingJ, TitusAR, HumphreyMB (2015) The TREM2-DAP12 signaling pathway in Nasu–Hakola disease: A molecular genetics perspective. Res Rep Biochem5, 89.
60.
PengQ, MalhotraS, TorchiaJA, KerrWG, CoggeshallKM, HumphreyMB (2010) TREM2-and DAP12-dependent activation of PI3K requires DAP10 and is inhibited by SHIP1. Sci Signal3, ra38.
61.
ZhaoY, WuX, LiX, JiangLL, GuiX, LiuY, SunY, ZhuB, Piña-CrespoJC, ZhangM, ZhangN, ChenX, BuG, AnZ, HuangT, XuH (2018) TREM2 is a receptor for β-amyloid that mediates microglial function. Neuron97, 1023–1031.
62.
CaoM, LiH, ZhaoJ, CuiJ, HuG (2019) Identification of age-and gender-associated long noncoding RNAs in the human brain with Alzheimer’s disease. Neurobiol Aging81, 116–126.
63.
FagerbergL, HallströmBM, OksvoldP, KampfC, DjureinovicD, OdebergJ, HabukaM, ahmasebpoorS, DanielssonA, EdlundK, AsplundA, SjöstedtE, LundbergE, SzigyartoCA, SkogsM, TakanenJO, BerlingH, TegelH, MulderJ, NilssonP, SchwenkJM, LindskogC, DanielssonF, MardinogluA, SivertssonÅ, FeilitzenK, ForsbergM, ZwahlenM, OlssonI, NavaniS, HussM, NielsenJ, PontenF, UhlénM (2014) Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol Cell Proteomics13, 397–406.
64.
SpäniC, SuterT, DerungsR, FerrettiMT, WeltT, WirthF, GerickeC, NitschRM, KulicL (2015) Reduced β-amyloid pathology in an APP transgenic mouse model of Alzheimer’s disease lacking functional B and T cells. Acta Neuropathol Commun3, 71.
65.
MerliniM, KirabaliT, KulicL, NitschRM, FerrettiMT (2018) Extravascular CD3+T cells in brains of Alzheimer disease patients correlate with tau but not with amyloid pathology: An immunohistochemical study. Neurodegener Dis18, 49–56.
